Mainland China

vivo officially launches VISION+ Mobile PhotoAwards 2021

vivo partners with National Geographic to host professional mobile photography competition BEIJING, June 7, 2021 /PRNewswire/ -- Today vivo officially launched the VISION+ Mobile PhotoAwards 2021 (hereafter referred to as VISION+ Mobile PhotoAwards), in partnership with National Geographic,...

2021-06-07 21:00 2217

KYMCO Announces Ionex EV League

BEIJING, June 7, 2021 /PRNewswire/ -- At the Beijing International Motorcycle Exhibition 2021, KYMCO announces Ionex EV League strategic alliance with Super SOCO and FELO Technology. From right: Zhang Jingyi, CEO of FELO Technology, and Sherman Xie...

2021-06-07 20:07 1926

Nium Signs Definitive Agreement to Acquire B2B Travel Payments Leader Ixaris

SINGAPORE and LONDON, June 7, 2021 /PRNewswire/ -- Nium, a leading global B2B payments platform, today announced that it has signed a definitive agreement to acquire Ixaris, a leader in travel payments optimisation. The transaction is expected to close early in the third quarter of 2021, subject ...

2021-06-07 17:00 2804

China makes great efforts to contain COVID-19, saves more lives: SCO Secretary-General

WUHAN, China, June 4, 2021 /PRNewswire/ -- China has made great efforts to contain the spread of COVID-19 and saved more lives, Secretary-General of the Shanghai Cooperation Organization (SCO) Vladimir Norov told Global Times Online on the sidelines of the SCO non-governmental friendship forum he...

2021-06-07 11:35 1525

Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Plus Paclitaxel/Cisplatin for the First-line Treatment of ESCC at ASCO 2021

SUZHOU, China, June 7, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced data from Phase 2 clinical study (KN046-204) of KN046(PD-L1/CTLA-4 bispecific antibody) plus paclitaxel/cisplatin for the first-line treatment of unresectable locally advanced, recurrent or metastatic e...

2021-06-07 10:11 6425

Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced NSCLC at ASCO 2021

* KN046 combined with platinum doublet chemotherapy is tolerated and has shown promising clinical benefit as IL treatment for stage IV NSCLC. * OS rate at 12 months and 15 months were both 74.9%; Similar survival was observed in patients with PD-L1≥1% and PD-L1<1%; * the median progression-f...

2021-06-07 10:10 6057

OriginCell Therapeutics Presents Positive Results of GPC3 CAR-T in HCC Trial at the 2021 ASCO Annual Meeting

SHANGHAI, June 7, 2021 /PRNewswire/ -- On June 4, 2021 (EST), OriginCell Therapeutics (Shanghai) Co., Ltd. ("OriginCell"), together with Lishui Central Hospital affiliated toZhejiang University and Shanghai Changzheng Hospital, presented the updated data from the on-going trial of Ori-CAR-001,...

2021-06-07 10:00 3118

Hyperice Named Official Recovery Technology Partner by League of Legends Pro League

SHANGHAI, June 7, 2021 /PRNewswire/ -- League of Legends Pro League (LPL) and  Hyperice, the industry leader in recovery technology and pioneer of percussion, vibration, dynamic air compression and thermal technology, today announced a partnership that names Hyperice the league's Official Recovery...

2021-06-07 10:00 2871

Poster Highlighting Clinical Data of KN046 Plus Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Pancreatic Cancer Is Presented at ASCO 2021

* As of January 15, 2021, 9 patients were included in the efficacy analysis and 17 patients in the safety analysis. ORR was 55.6%, and DCR was 88.9%. * The updated results from this Phase II study will be presented at an upcoming medical meeting. A phase III clinical study of KN046 in combinat...

2021-06-07 09:53 5629

CSOP Asset Management Ltd. Chooses SS&C to Support Operations

WINDSOR, Conn., June 7, 2021 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced thatHong Kong's CSOP Asset Management Ltd. has selected Eze Investment Suite for order management and portfolio accounting. Eze Investment Suite provides the flexibility CSOP required for ...

2021-06-07 09:00 10220

WeBank and SMU Nurture Future-Ready Fintech Talent with Blockchain Courses

SHENZHEN, China, June 7, 2021 /PRNewswire/ -- WeBank, the world's leading digital bank and the first digital-only bank inChina, announced that its summer enrichment programme onFISCO BCOS[1] Blockchain Experience at the Singapore Management University (SMU), a premier university in Asia internati...

2021-06-07 09:00 3240

Ascletis Received China IND Approval of Its FXR Agonist ASC42 for Chronic Hepatitis B Indication

HANGZHOU, China and SHAOXING, China, June 7, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its drug candidate ASC42 to conduct clinical trials for ch...

2021-06-07 08:30 2771

Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-07 08:00 7196

Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-07 08:00 7358

Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-07 08:00 7158

Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-07 08:00 7031

Arctic Vision Announces Exclusive Licensing Agreement with Olympic Ophthalmics for iTEAR®100 for the Treatment of Dry Eye Disease in Greater China, South Korea and ASEAN countries

ISSAQUAH, Wash. and SHANGHAI, June 7, 2021 /PRNewswire/ -- Arctic Vision, a clinical stage biotech company focusing on innovative ophthalmology therapies for pan-ocular diseases, and Olympic Ophthalmics, a U.S.-based medical technology company pioneering neuromodulation treatments for ophthalmic ...

2021-06-07 08:00 1933

Wood Mackenzie announces inaugural Power & Renewables APAC Conference

Industry leaders to discuss climate change policies and net-zero impact on APAC markets First public presentation of Wood Mackenzie Lens® Power SINGAPORE, June 7, 2021 /PRNewswire/ -- Wood Mackenzie invites registration for its inaugural Power & Renewables Asia Pacific (APAC) Conference onJune 2...

2021-06-07 07:00 2796

Primavera Capital Acquires Greater China Business of Mead Johnson from Reckitt Benckiser Group

BEIJING, June 6, 2021 /PRNewswire/ -- Primavera Capital Group ("Primavera") today announces that it has signed a definitive agreement with Reckitt Benckiser Group plc ("Reckitt"), a world's leading consumer health, nutrition, and hygiene company, to acquire theGreater China business of the Mead J...

2021-06-06 12:00 4052

Ucommune International Ltd. Announces Unaudited First Quarter 2021 Financial Results

BEIJING, Jun. 5, 2021 /PRNewswire/ -- Ucommune International Ltd. (NASDAQ: UK) ("Ucommune" or the "Company"), a leading agile office space manager and provider inChina, today announced its unaudited financial results for the first quarter endedMarch 31, 2021. First Quarter 2021 Financial Highli...

2021-06-05 04:30 15996
1 ... 525526527528529530531 ... 815